Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
27 Settembre 2023 - 3:09PM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) products for cancer, today announced three
preclinical poster presentations at the Society for Immunotherapy
of Cancer (SITC) Annual Meeting November 1-5, 2023,
in San Diego, CA. These presentations will focus on the
Company’s next generation AlloCAR T platform technologies and the
foundation for an early-stage solid tumor product candidate,
ALLO-182.
“We are excited to share some of the groundbreaking work from
our research team as we define next generation platform
technologies that are designed to enhance engraftment and expansion
of our AlloCAR TTM product candidates,” said Zachary Roberts,
M.D., Ph.D., Executive Vice President, Research & Development
and Chief Medical Officer. “We believe this important and
foundational work could expand the potential of off-the-shelf CAR T
products by improving their persistence and anti-tumor activity
across multiple targets while also creating a path to reducing the
intensity of conditioning therapy.”
Allogene Abstracts:
DAGGER™ PLATFORM TECHNOLOGYPreclinical
Evaluation of Allogeneic CD19 CAR T Cells Expressing an
Anti-Rejection CD70 CAR Presenter: Elvin Lauron,
Ph.D. Abstract: 279Poster Session Display Date and
Time: Friday, Nov. 3, 2023, 9:00 a.m. - 7:00 p.m. PTLocation:
Exhibit Halls A and B1
CLOAK™ PLATFORM TECHNOLOGYGeneration of
Immune-Evasive Allogeneic CAR T Cells by Inactivation of the HLA
Transcriptional Regulator RFX5 and Disruption of the Immune
Synapse Presenter: Hsin-Yuan Cheng, Ph.D. Abstract:
302Poster Session Display Date and Time: Saturday, Nov. 4,
2023, 9:00 a.m. - 8:30 p.m. PTLocation: Exhibit Halls A and
B1
SOLID TUMOR TARGET
(ALLO-182)Preclinical Development and
Characterization of Allogeneic CAR T Cells Targeting Claudin18.2
Positive Tumors Presenter: Joanne Li, Ph.D.Abstract:
283Poster Session Display Date and Time: Friday, Nov. 3, 2023,
9:00 a.m. - 7:00 p.m. PTLocation: Exhibit Halls A and B1
About Allogene
TherapeuticsAllogene Therapeutics, with headquarters
in South San Francisco, is a clinical-stage biotechnology
company pioneering the development of allogeneic chimeric antigen
receptor T cell (AlloCAR T™) products for cancer. Led by a
management team with significant experience in cell therapy,
Allogene is developing a pipeline of “off-the-shelf” CAR T product
candidates with the goal of delivering readily available cell
therapy on-demand, more reliably, and at greater scale to more
patients. For more information, please visit www.allogene.com,
and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for
AllogeneThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should,” “designed to” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Forward-looking statements include statements regarding
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: Allogene’s ability to
democratize CAR T access; Allogene’s ability to deliver readily
available off-the shelf cell therapy on-demand, more reliably, and
at greater scale to more patients; and the modes of action and the
therapeutic effects of Allogene’s product candidates including
their ability to treat cancers at various stages. Various factors
may cause material differences between Allogene’s expectations and
actual results, including risks and uncertainties related to: our
product candidates are based on novel technologies, which makes it
difficult to predict the time and cost of product candidate
development and obtaining regulatory approval. These and other
risks are discussed in greater detail in Allogene’s filings with
the SEC, including without limitation under the “Risk Factor”
Heading in its Form 10-Q filed for the quarter ended June 30, 2023.
Any forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™, Cloak™ and Dagger™ are trademarks of Allogene
Therapeutics, Inc.
Allogene’s AlloCAR T™ programs utilize Cellectis
technologies.
Allogene Media/Investor Contact:Christine
CassianoChief Corporate Affairs & Brand Strategy Officer(714)
552-0326Christine.Cassiano@allogene.com
Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Allogene Therapeutics (NASDAQ:ALLO)
Storico
Da Giu 2023 a Giu 2024